Differential behavior of bone turnover markers in women with bone metastatic breast cancer or osteoporosis

Background: This study was designed to describe bone turnover marker (BTM) profiles in women. Patients and methods: In all, 197 patients (age 61 [36-90] years) comprising five groups were studied: osteoporosis with (OPBP+) or without (OPBP-) bisphosphonate use; bone metastatic breast cancer with (BMBP+) or without (BMBP-) BP use; and healthy controls without BP (CBP-) use. Procollagen type 1 amino-terminal propeptide (P1NP) and carboxy-terminal telopeptide of type 1 collagen (CTX) were analyzed. Results: The medians [25%-75%; ng/mL] for P1NP were as follows: BMBP- (236.95 [165.0-328.0]) > CBP- (47.25 [33.5-63.7]) = OPBP- (50.9 [37.4-63.9]) > BMBP+(26.9 [11.8-46.3]) = OPBP+ (19.5 [12.6-27.3]). The medians [25% -75%; ng/mL] for CTX were as follows: BMBP- (0.567 [0.457-0.803]) = OPBP- (0.360 [0.318-0.650]) > CBP- (0.297 [0.203-0.402]) > BMBP+(0.101 [0.052-0.202]) = OPBP+(0.141 [0.047-0.186]). Conclusion: P1NP > 145 ng/mL completely differentiated those with BMs. CTX < 0.200 ng/mL differentiated those using BPs.